Cipla shares slide 4.5% after USFDA flags compliance gaps at key Lanreotide supplier site

Regulatory action at Pharmathen’s main manufacturing site in Greece could potentially disrupt supplies of one of Cipla’s ...
CNBCTV18

Cipla shares extend losses to nearly 5% after USFDA discloses observations on key partner

Cipla has a partnership with Pharmathen to commercialise Lanreotide in the US market, and the regulatory action has weighed ...
The American Journal of Managed Care

Lanreotide Approved for Gastroenteropancreatic Neuroendocrine Tumors

The approval was based on the results of a clinical trial that demonstrated improved PFS in patients on lanreotide. While the median PFS in the placebo arm was 16 months, patients in the lanreotide ...
CNBCTV18

Cipla evaluating US FDA Form 483 observations on supply partner Pharmathen

Cipla clarified that its supply partner Pharmathen received nine USFDA Form 483 observations during a November 2025 ...
ascopubs.org

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled ...

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus ...
The American Journal of Managed Care

Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs

An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the ...
Medscape

CLARINET Results: Lanreotide First Line for Metastatic NETs

The somatostatin analogue lanreotide (Somatuline, Ipsen) is significantly better than placebo for controlling progression of many types of metastatic neuroendocrine tumors (NETs), according to the ...
Medindia

Side effect(s) of Lanreotide

Review the side-effects of Lanreotide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
Nature

Interval between lanreotide injections can be increased without loss of efficacy

Insulin-like growth factor I and growth hormone levels were adequately controlled on 4-weekly injections in nine patients. In these patients the effect of increasing the time interval between ...
ascopubs.org

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
Healio

Lanreotide not harmful for HbA1c, lipid levels in acromegaly

Please provide your email address to receive an email when new articles are posted on . Lanreotide autogel did not increase lipid or glucose levels in patients with acromegaly, researchers conducting ...
The New England Journal of Medicine

Cabergoline plus Lanreotide for Ectopic Cushing's Syndrome

A 35-year-old man had a clinical picture suggestive of the ectopic corticotropin syndrome related to a carcinoid tumor; biochemical and hormonal tests confirmed the diagnosis. Somatostatin-receptor ...